Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J
- Drugmaker says it’s had early talks with Amgen, Sanofi, J&J
- Shares had lost 27% this year through Tuesday’s close
This article is for subscribers only.
Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.
Amgen Inc., Johnson & Johnson and Sanofi are separately engaged in preliminary discussions with Horizon, the company said in a statement on Tuesday. There’s no certainty that any of the talks will lead to an offer. Dublin-based Horizon makes drugs for rare autoimmune and inflammatory diseases.